IL17A and neoplasm: In addition to inhibiting cancer cell migration and invasion, bi-specific inhibitors that target both MMP-9 and IL-17 can increase the selectivity of treatment to those cancer cells that express both targets, in which the cross-reactivity and synergistic action of these targets strongly promote cancer cell invasion [36, 37], to improve tumor growth inhibition.